Literature DB >> 33467995

Self-clearance of Mycobacterium tuberculosis infection: implications for lifetime risk and population at-risk of tuberculosis disease.

Jon C Emery1, Alexandra S Richards1, Katie D Dale2,3, C Finn McQuaid1, Richard G White1, Justin T Denholm2, Rein M G J Houben1.   

Abstract

Background: it is widely assumed that individuals with Mycobacterium tuberculosis (Mtb) infection remain at lifelong risk of tuberculosis (TB) disease. However, there is substantial evidence that self-clearance of Mtb infection can occur. We infer a curve of self-clearance by time since infection and explore its implications for TB epidemiology. Methods and findings: data for self-clearance were inferred using post-mortem and tuberculin-skin-test reversion studies. A cohort model allowing for self-clearance was fitted in a Bayesian framework before estimating the lifetime risk of TB disease and the population infected with Mtb in India, China and Japan in 2019. We estimated that 24.4% (17.8-32.6%, 95% uncertainty interval (UI)) of individuals self-clear within 10 years of infection, and 73.1% (64.6-81.7%) over a lifetime. The lifetime risk of TB disease was 17.0% (10.9-22.5%), compared to 12.6% (10.1-15.0%) assuming lifelong infection. The population at risk of TB disease in India, China and Japan was 35-80% (95% UI) smaller in the self-clearance scenario. Conclusions: the population with a viable Mtb infection may be markedly smaller than generally assumed, with such individuals at greater risk of TB disease. The ability to identify these individuals could dramatically improve the targeting of preventive programmes and inform TB vaccine development, bringing TB elimination within reach of feasibility.

Entities:  

Keywords:  Mycobacterium tuberculosis; epidemiology; infection; mathematical modelling; self-clearance

Mesh:

Year:  2021        PMID: 33467995      PMCID: PMC7893269          DOI: 10.1098/rspb.2020.1635

Source DB:  PubMed          Journal:  Proc Biol Sci        ISSN: 0962-8452            Impact factor:   5.349


  50 in total

Review 1.  Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion.

Authors:  D Menzies
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

Review 2.  Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis.

Authors:  Jason R Andrews; Farzad Noubary; Rochelle P Walensky; Rodrigo Cerda; Elena Losina; C Robert Horsburgh
Journal:  Clin Infect Dis       Date:  2012-01-19       Impact factor: 9.079

3.  Endogenous reactivation and exogenous reinfection: their relative importance with regard to the development of non-primary tuberculosis.

Authors:  G Canetti; I Sutherland; E Svandova
Journal:  Bull Int Union Tuberc       Date:  1972-02

4.  The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection.

Authors:  E Vynnycky; P E Fine
Journal:  Epidemiol Infect       Date:  1997-10       Impact factor: 2.451

Review 5.  Tuberculosis vaccines and prevention of infection.

Authors:  Thomas R Hawn; Tracey A Day; Thomas J Scriba; Mark Hatherill; Willem A Hanekom; Thomas G Evans; Gavin J Churchyard; James G Kublin; Linda-Gail Bekker; Steven G Self
Journal:  Microbiol Mol Biol Rev       Date:  2014-12       Impact factor: 11.056

6.  The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands.

Authors:  I Sutherland; E Svandová; S Radhakrishna
Journal:  Tubercle       Date:  1982-12

7.  Tuberculosis Disease in Children and Adolescents on Therapy With Antitumor Necrosis Factor-ɑ Agents: A Collaborative, Multicenter Paediatric Tuberculosis Network European Trials Group (ptbnet) Study.

Authors:  Antoni Noguera-Julian; Joan Calzada-Hernández; Folke Brinkmann; Robindra Basu Roy; Olga Bilogortseva; Michael Buettcher; Isabel Carvalho; Vira Chechenyeva; Lola Falcón; Florian Goetzinger; Carmelo Guerrero-Laleona; Peter Hoffmann; Marija Jelusic; Tim Niehues; Iveta Ozere; Fiona Shackley; Elena Suciliene; Steven B Welch; Elisabeth H Schölvinck; Nicole Ritz; Marc Tebruegge
Journal:  Clin Infect Dis       Date:  2020-12-17       Impact factor: 9.079

8.  Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions.

Authors:  Nicolas A Menzies; Emory Wolf; David Connors; Meghan Bellerose; Alyssa N Sbarra; Ted Cohen; Andrew N Hill; Reza Yaesoubi; Kara Galer; Peter J White; Ibrahim Abubakar; Joshua A Salomon
Journal:  Lancet Infect Dis       Date:  2018-04-10       Impact factor: 25.071

Review 9.  Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies.

Authors:  Hanif Esmail; Clifton E Barry; Robert J Wilkinson
Journal:  Drug Discov Today       Date:  2011-12-20       Impact factor: 7.851

Review 10.  The ongoing challenge of latent tuberculosis.

Authors:  H Esmail; C E Barry; D B Young; R J Wilkinson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-05-12       Impact factor: 6.237

View more
  5 in total

1.  Mathematical modelling of the progression of active tuberculosis: Insights from fluorography data.

Authors:  Konstantin Konstantinovich Avilov; Alexei Alexeevich Romanyukha; Evgeny Mikhailovich Belilovsky; Sergey Evgenevich Borisov
Journal:  Infect Dis Model       Date:  2022-06-30

2.  Trends, Mechanisms, and Racial/Ethnic Differences of Tuberculosis Incidence in the US-Born Population Aged 50 Years or Older in the United States.

Authors:  Sun Kim; Ted Cohen; C Robert Horsburgh; Jeffrey W Miller; Andrew N Hill; Suzanne M Marks; Rongxia Li; J Steve Kammerer; Joshua A Salomon; Nicolas A Menzies
Journal:  Clin Infect Dis       Date:  2022-05-03       Impact factor: 20.999

3.  Blood transcriptomics reveal the evolution and resolution of the immune response in tuberculosis.

Authors:  Olivier Tabone; Raman Verma; Pranabashis Haldar; Anne O'Garra; Akul Singhania; Probir Chakravarty; William J Branchett; Christine M Graham; Jo Lee; Tran Trang; Frederic Reynier; Philippe Leissner; Karine Kaiser; Marc Rodrigue; Gerrit Woltmann
Journal:  J Exp Med       Date:  2021-09-07       Impact factor: 14.307

4.  Achieving a "step change" in the tuberculosis epidemic through comprehensive community-wide intervention: a model-based analysis.

Authors:  Sourya Shrestha; Emily A Kendall; Rebekah Chang; Roy Joseph; Parastu Kasaie; Laura Gillini; Anthony Todd Fojo; Michael Campbell; Nimalan Arinaminpathy; David W Dowdy
Journal:  BMC Med       Date:  2021-10-14       Impact factor: 11.150

Review 5.  After 100 Years of BCG Immunization against Tuberculosis, What Is New and Still Outstanding for This Vaccine?

Authors:  Mario Alberto Flores-Valdez
Journal:  Vaccines (Basel)       Date:  2021-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.